We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MicroRNA Panel Appears Predictive for Progression to Multiple Myeloma

By LabMedica International staff writers
Posted on 12 Oct 2015
Print article
Image: Micrograph of bone marrow aspirate showing the histological correlate of multiple myeloma (Photo courtesy of Wikimedia Commons).
Image: Micrograph of bone marrow aspirate showing the histological correlate of multiple myeloma (Photo courtesy of Wikimedia Commons).
Eleven microRNAs (miRNAs) were found to be significantly decreased in both bone marrow (BM) and serum of multiple myeloma (MM) patients in comparison with controls and may form the basis for a blood test to diagnose the disease.

miRNAs are fragments of RNA about 20 nucleotides long that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

According to the [US] National Cancer Institute, nearly 27,000 individuals will be diagnosed with myeloma in the US in 2015, resulting in about 11,240 deaths. Myeloma is the 14th most common cancer and the third most common blood cancer, after lymphoma and leukemia. Despite these statistics, a convenient screening test for MM has been lacking.

Investigators at the [US] National Institutes of Health (Bethesda, MD, USA) looked at miRNAs linked to MM as the basis for a possible diagnostic screening test. Towards this end, they analyzed fluid taken from the bone marrow of 20 patients with myeloma, which resulted in the identification of 111 miRNAs that showed a two-fold or greater difference from levels observed in eight control samples. Approximately 60% of the miRNAs were down-regulated and 38% were up-regulated.

Eleven miRNAs were significantly decreased in both BM and serum of MM patients in comparison with controls. Evaluation of these miRNAs in plasma of a separate cohort of MM patients and controls confirmed significantly abnormal levels of the miRNAs let-7a, let-7b, let-7i, miR-15b, miR-16, and miR-20a in both serum and plasma.

Investigators examined the pattern of myeloma miRNAs in precursor diseases to monitor changes as the disease progressed. They analyzed serum samples in 17 patients with MGUS (monoclonal gammopathy of undetermined significance), 17 with SMM (smoldering myeloma), 13 with myeloma, and 12 healthy controls. They found that only 4 of the 11 miRNAs (36%) that were reduced in the myeloma serum samples were lower in the MGUS samples. Eight of the 11 (73%) miRNAs were decreased in SMM plasma samples. However, three (27%) were significantly reduced only in the myeloma samples.

These findings suggested that these miRNAs were detectable in abnormal levels in the peripheral blood of patients with plasma cell proliferation and could play a role in aberrant plasma cell proliferation and disease progression.

"Our findings suggest that the antiproliferative and pro-apoptotic miRNAs, such as the let-7 family members, are down-regulated in multiple myeloma's microenvironment. These findings suggest that measuring expression of miRNAs associated with myeloma progression in the peripheral blood may hold promise for predicting disease progression in MGUS and SMM," said senior author Dr. Katherine R. Calvo, a researcher in the hematology section of the department of laboratory medicine of the [US] National Institutes of Health.

The study was published in the September 30, 2015, online edition of the Journal of Molecular Diagnostics.

Related Links:

[US] National Institutes of Health


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.